Cargando…

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

BACKGROUND: Azvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19. However, the impact of LDH levels in COVID-19 patients receiving Azvudine treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Manyun, Dian, Yating, Sun, Yuming, Chen, Wangqing, Zhu, Wu, Deng, Guangtong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619747/
https://www.ncbi.nlm.nih.gov/pubmed/37920449
http://dx.doi.org/10.3389/fcimb.2023.1237277
_version_ 1785130053495947264
author Mao, Manyun
Dian, Yating
Sun, Yuming
Chen, Wangqing
Zhu, Wu
Deng, Guangtong
author_facet Mao, Manyun
Dian, Yating
Sun, Yuming
Chen, Wangqing
Zhu, Wu
Deng, Guangtong
author_sort Mao, Manyun
collection PubMed
description BACKGROUND: Azvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19. However, the impact of LDH levels in COVID-19 patients receiving Azvudine treatment remains unclear. METHODS: In this retrospective cohort study, we analyzed the data of 351 hospitalized COVID-19 patients who were consecutively treated with Azvudine, with or without high LDH levels. The clinical features, treatment strategies and prognosis data were collected and analyzed. RESULTS: Among the 351 hospitalized patients with COVID-19 treated with Azvudine (119 with high-LDH levels), the median age was 69 years (range 58–78), and 213 (60.7%) were male. Common symptoms included cough (86.0%), expectoration (73.5%), fever (69.8%), polypnea (47.6%) and poor appetite (46.4%). Patients with high LDH levels exhibited significantly elevated leucocyte and neutrophil counts, elevated level of myocardial enzymes, as well as higher levels of inflammatory markers such as interleukin-6, interleukin-10, procalcitonin, C reactive protein, ferritin, and prolonged erythrocyte sedimentation rate upon admission. COVID-19 patients with high-LDH levels had higher rates of corticosteroid therapy, non-invasive and invasive mechanical ventilation, worsened and death (2.5% vs. 0%). The Cox proportional hazard model demonstrated that high LDH levels (adjusted hazard ratio = 5.27; 95% confidence interval: 1.19, 14.50) were associated with a more unfavorable composite disease progression outcome among COVID-19 patients treated with Azvudine, after accounting for potential confounding variables. CONCLUSION: High-LDH levels predict a worse composite disease progression outcome in COVID-19 patients treated with Azvudine.
format Online
Article
Text
id pubmed-10619747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106197472023-11-02 Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine Mao, Manyun Dian, Yating Sun, Yuming Chen, Wangqing Zhu, Wu Deng, Guangtong Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Azvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19. However, the impact of LDH levels in COVID-19 patients receiving Azvudine treatment remains unclear. METHODS: In this retrospective cohort study, we analyzed the data of 351 hospitalized COVID-19 patients who were consecutively treated with Azvudine, with or without high LDH levels. The clinical features, treatment strategies and prognosis data were collected and analyzed. RESULTS: Among the 351 hospitalized patients with COVID-19 treated with Azvudine (119 with high-LDH levels), the median age was 69 years (range 58–78), and 213 (60.7%) were male. Common symptoms included cough (86.0%), expectoration (73.5%), fever (69.8%), polypnea (47.6%) and poor appetite (46.4%). Patients with high LDH levels exhibited significantly elevated leucocyte and neutrophil counts, elevated level of myocardial enzymes, as well as higher levels of inflammatory markers such as interleukin-6, interleukin-10, procalcitonin, C reactive protein, ferritin, and prolonged erythrocyte sedimentation rate upon admission. COVID-19 patients with high-LDH levels had higher rates of corticosteroid therapy, non-invasive and invasive mechanical ventilation, worsened and death (2.5% vs. 0%). The Cox proportional hazard model demonstrated that high LDH levels (adjusted hazard ratio = 5.27; 95% confidence interval: 1.19, 14.50) were associated with a more unfavorable composite disease progression outcome among COVID-19 patients treated with Azvudine, after accounting for potential confounding variables. CONCLUSION: High-LDH levels predict a worse composite disease progression outcome in COVID-19 patients treated with Azvudine. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10619747/ /pubmed/37920449 http://dx.doi.org/10.3389/fcimb.2023.1237277 Text en Copyright © 2023 Mao, Dian, Sun, Chen, Zhu and Deng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Mao, Manyun
Dian, Yating
Sun, Yuming
Chen, Wangqing
Zhu, Wu
Deng, Guangtong
Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
title Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
title_full Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
title_fullStr Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
title_full_unstemmed Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
title_short Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
title_sort lactate dehydrogenase predicts disease progression outcome in covid-19 patients treated with azvudine
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619747/
https://www.ncbi.nlm.nih.gov/pubmed/37920449
http://dx.doi.org/10.3389/fcimb.2023.1237277
work_keys_str_mv AT maomanyun lactatedehydrogenasepredictsdiseaseprogressionoutcomeincovid19patientstreatedwithazvudine
AT dianyating lactatedehydrogenasepredictsdiseaseprogressionoutcomeincovid19patientstreatedwithazvudine
AT sunyuming lactatedehydrogenasepredictsdiseaseprogressionoutcomeincovid19patientstreatedwithazvudine
AT chenwangqing lactatedehydrogenasepredictsdiseaseprogressionoutcomeincovid19patientstreatedwithazvudine
AT zhuwu lactatedehydrogenasepredictsdiseaseprogressionoutcomeincovid19patientstreatedwithazvudine
AT dengguangtong lactatedehydrogenasepredictsdiseaseprogressionoutcomeincovid19patientstreatedwithazvudine